NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
September 17, 2017 in NanOlogy in the News

Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment

NanOlogy 0 Like Post Comments Off on Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment
Read More
Post placeholder image
September 17, 2017 in NanOlogy in the News

‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers

NanOlogy 0 Like Post Comments Off on ‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers
Read More
Post placeholder image
September 17, 2017 in NanOlogy in the News

DFB Pharmaceuticals Forms NanOlogy™

NanOlogy 0 Like Post Comments Off on DFB Pharmaceuticals Forms NanOlogy™
Read More
Post placeholder image
September 17, 2017 in NanOlogy in the News

DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses

NanOlogy 0 Like Post Comments Off on DFB Pharmaceuticals Forms NanOlogy™ for Clinical Development of Naked Nanoparticle Platform to Treat Cancer and Related Illnesses
Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal